Reata Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Reata Pharmaceuticals, Inc.
Orphan drugs and COVID-19 products are among the latest filings under review by the European Medicines Agency for potential pan-EU approval.
SciNeuro’s latest in-licensing deals include three assets for major neurodegenerative diseases from Lilly and Mabylon, but the Chinese bioventure is looking beyond the shopping spree at what it sees as outstanding CNS needs.
Meetings have continued to be sparse through 2021, but there will end up being nearly as many panels on withdrawing approved uses as on approving new ones.
The diuretic bumetanide had shown potential to improve the core symptoms of children and adolescents with autism in small studies but has failed to demonstrate any sign of effectiveness in two late-stage trials.